NCT01851850已完成3 期
Continue Providing Care for Patient Who Participated in the BIA 9-1067-302 Clinical Trial
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 1
- 试验地点
- 1
- 主要终点
- off periods
研究概览
简要总结
The purpose of the study is to extend the use of opicapone 25 or 50mg once per day by subjects who participated in the BIA 9-1067-302 clinical trial according form 4a for additional three years.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 30 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •clinical diagnosis with PD
- •subjects who are willing to participate in the trial.
- •subjects who participated in the BIA 9-1067-302 clinical trial.
排除标准
- •subjects who didn't take part at the BIA 9-1067-302 clinical trial.
研究组 & 干预措施
Drug
Experimental
干预措施: Opicapone (Drug)
结局指标
主要结局
off periods
时间窗: 6 month
number of "off" periods during the day without worsening dyskinesia.
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
不适用
Continuation Treatment Protocol for Patients Who Participated in the Adagio TVP 1012/501 Clinical TrialParkinson DiseaseNCT01709461Rabin Medical Center12
已完成
2 期
Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating ElotuzumabMultiple MyelomaNCT02719613Bristol-Myers Squibb67
招募中
3 期
A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored StudyCancerNCT05862285Hoffmann-La Roche100
进行中（未招募）
1 期
A Rollover Study of CC-122Non-Hodgkin LymphomaNCT05688475Bristol-Myers Squibb12
已完成
2 期
Roll-over Study to Continue Treatment With the Investigational Drug Rogaratinib and to Further Test Its SafetyCancerNCT04125693Bayer1